Paracelsian Inc (PRLN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John H. Farro who wrote (498)	9/16/1996 7:10:00 PM
From: Richard Mazzarella	of 4342

Paracelsian Presents At Cap Cure Conference ITHACA, N.Y., Sept. 16 /PRNewswire/ -- Paracelsian Inc reported that it had been invited to present the results of its research in prostate cancer at the third annual CaP CURE Scientific Retreat held at Incline Village, North Lake Tahoe, Nevada. Also presenting at this retreat were approximately 85 other speakers representing the latest developments in the various fields of prostate cancer research ranging from diagnostics to gene therapy. Presenting for the Company was Dr. John Babish, Vice President and Chief Science Officer. Dr. Babish described the latest results of the Company's research including results of the seven patient, compassionate safety and dose-determination clinical trial completed in July 1996 for AndroCar(TM). Dr. Babish reported that "this was a very influential group of researchers and scientists who shared exciting results and approaches to this serious disease. It was gratifying to be a part of this work and these presentations." Dr. Babish's presentation also focused on how the Company applies its signal transduction technology for prostate cancer research and the results of its research in the laboratory and in the clinic. The Company is developing AndroCar and further clinical trials are scheduled for October and November of 1996. The CaP CURE Scientific Retreats began as a vehicle for interaction between the academic and biotech communities with the goal of assisting those involved in solving the riddles of prostate cancer. Now in its third year, it continues to chronicle the amazing explosion of scientific knowledge about this devastating disease in an informal atmosphere. Paracelsian is a biotechnology company engaged in the discovery of pharmaceuticals from herbal sources and the development and marketing of tests for improved cancer diagnosis and environmental carcinogens, utilizing the Company's proprietary signal transduction technology. SOURCE Paracelsian, Inc.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next